1College of Science, Department of Chemistry, University of Kerbala, Iraq
2College of Science, Department of Chemistry, University of Al-Mustansiriyah, Iraq
*Corresponding Author: Narjis Hadi Al-Saadi, College of Science, Department of Chemistry, University of Kerbala, Iraq, Email: narjis.h@uokerbala.edu.iq
Online published on 26 September, 2019.
Transforming growth factor β1 (TGF β1) is one of the proteins which has a multifunctional role in breast cancer. It is considered an inhibitor in early stages and promoter in advanced stages of breast cancer.
The aim of this study is to know the benefit of using TGF β1 as predictor marker in breast cancer patients in different stages of the disease.
Transforming growth factor β1 were determined from 52 patients with breast cancer in the early stage of the tumor (I+II) 61% and advanced stage (III+IV) 39% and 25 subjects as a control group by using Enzyme Linked Immunosorbent Assay (ELISA).
The results showed a high level of TGF β1 (p< 0.05) in breast cancer patients compared with the control group. Depending on the stage of the tumor, TGF β1 was more level in these patients with stage II than stage I and stage IV (p< 0.03, 0.029) respectively. So this study showed no any significant differences between the early stage of the tumor and advanced stage of the tumor.
TGF β1, Breast cancer, serum
